Grandall Law Firm (Hangzhou)
Supplementary Legal Opinion II
Regarding
Zhejiang Tailin Bio-technology Co., Ltd.
Issuance of Convertible Bonds to Unspecified Targets
To: Zhejiang Tailin Bio-technology Co., Ltd.
Grandall Law Firm (Hangzhou) hereby issues the following supplementary legal opinion for Zhejiang Tailin Bio-technology Co., Ltd.'s issuance of convertible bonds to unspecified targets, in accordance with relevant laws, administrative regulations, and the business standards, ethical norms, and diligence recognized by the legal profession.
Part One: Introduction
As the legal advisor engaged by Zhejiang Tailin Bio-technology Co., Ltd. for the issuance of convertible bonds to unspecified targets, our firm issued the "Grandall Law Firm (Hangzhou) Legal Opinion on the Listing of Zhejiang Tailin Bio-technology Co., Ltd.'s Issuance of Convertible Bonds to Unspecified Targets" (hereinafter referred to as the "Legal Opinion") and the "Grandall Law Firm (Hangzhou) Lawyer's Work Report on Zhejiang Tailin Bio-technology Co., Ltd.'s Issuance of Convertible Bonds to Unspecified Targets" (hereinafter referred to as the "Lawyer's Work Report") on April 21, 2026.
On May 19, 2026, the Shenzhen Stock Exchange issued the Inquiry Letter (2026) 020044 regarding the application for the issuance of convertible bonds to unspecified targets by Zhejiang Tailin Bio-technology Co., Ltd. (hereinafter referred to as the "Inquiry Letter"). Our firm's lawyers conducted supplementary verification and provided explanations on the matters requiring verification and explanation in the "Inquiry Letter," and issued the "Grandall Law Firm (Hangzhou) Supplementary Legal Opinion I on the Listing of Zhejiang Tailin Bio-technology Co., Ltd.'s Issuance of Convertible Bonds to Unspecified Targets" (hereinafter referred to as "Supplementary Legal Opinion I") on June 3, 2026.
On July 1, 2026, the company's board of directors adjusted the issuance plan. Our firm's lawyers conducted supplementary verification on this adjustment and issued this Supplementary Legal Opinion.
This Supplementary Legal Opinion is issued in accordance with relevant laws, regulations, and the business standards, ethical norms, and diligence recognized by the legal profession, for Zhejiang Tailin Bio-technology Co., Ltd.'s issuance of convertible bonds to unspecified targets.
This Supplementary Legal Opinion supplements the "Lawyer's Work Report" and the "Legal Opinion." This Supplementary Legal Opinion should be used in conjunction with the "Lawyer's Work Report" and the "Legal Opinion." In case of any inconsistency between the "Lawyer's Work Report" and the "Legal Opinion" and this Supplementary Legal Opinion, this Supplementary Legal Opinion shall prevail. Unless otherwise stated in the context, the statements and definitions made by our firm and its lawyers in the "Lawyer's Work Report" and the "Legal Opinion" shall apply to this Supplementary Legal Opinion.
Part Two: Main Body
I. Approval of the Revised Issuance Plan
Our firm's lawyers conducted the following verification:
- Reviewed the meeting materials of the issuer's Fourth Board of Directors' Fourteenth Meeting.
Our firm's lawyers confirmed:
- Approval of the Issuance Plan by the Issuer's Board of Directors
On July 1, 2026, the issuer held the Fourth Board of Directors' Fourteenth Meeting, which deliberated and approved the proposals related to the revised issuance.
- Revised Issuance Plan of the Issuer
Based on the relevant content of the "Proposal on the Issuance Plan of Convertible Bonds to Unspecified Targets (Revised Draft)" approved by the Fourth Board of Directors' Fourteenth Meeting of the issuer, the revised issuance plan of the issuer is as follows:
(1) Use of Raised Funds
Before adjustment:
The total amount of funds to be raised by the company through the issuance of convertible bonds to unspecified targets shall not exceed RMB 230,000,000.00 (inclusive), which, after deducting issuance expenses, will be used for the following projects: